Financial Performance - The company reported a revenue of 500 million RMB for the first half of 2023, representing a 15% increase compared to the same period in 2022[21]. - The company achieved a revenue of CNY 1,089,986,468.37 in the first half of 2023, representing a growth of 27.08% compared to the same period last year[28]. - Net profit attributable to shareholders reached CNY 207,062,486.74, an increase of 37.65% year-on-year[28]. - The company reported a basic earnings per share of CNY 0.3572, up 38.02% from the previous year[28]. - The company reported a significant increase in user data, with a total of 1.5 million active users, representing a growth of 25% year-over-year[64]. - The revenue for the first half of 2023 reached 500 million RMB, a 15% increase compared to the same period last year[65]. - The company reported a revenue of 1.2 billion RMB for the first half of 2023, representing a year-over-year increase of 15%[67]. - Future guidance indicates a projected revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion strategies[65]. - Future outlook includes a revenue growth target of 25% for the full year 2023, driven by market expansion and new product launches[21]. Profitability and Margins - The gross profit margin improved to 45%, up from 42% in the previous year, indicating better cost management and pricing strategies[21]. - The gross margin for the first half of 2023 improved to 45%, up from 42% in the previous year, reflecting better cost management[65]. - The gross profit margin for the patient monitoring segment was 54.04%, up by 2.59% from the previous year[97]. Research and Development - Research and development expenses increased by 30% year-on-year, reflecting the company's commitment to innovation[21]. - The company plans to invest 100 million RMB in R&D over the next two years to accelerate innovation and product development[65]. - The company is actively pursuing innovation in medical devices, as evidenced by the registration of new technologies like the blood oxygen saturation monitor and multi-parameter health monitor[61]. - The company is focusing on innovative solutions for maternal and fetal health, as evidenced by the development of the fetal mother dynamic ECG detection device[55]. - The company has a robust pipeline of new products, with multiple devices registered for use, indicating a strong commitment to research and development in the medical device industry[70][73]. Product Development and Launches - The company plans to launch three new products in the next quarter, focusing on advanced diagnostic technologies[21]. - New product development includes the launch of a digital ECG machine and a dynamic blood pressure recorder, both expected to enhance diagnostic capabilities[67]. - The company is expanding its product line with new devices such as the fetal heart rate monitor and the ambulatory ECG system, which are also in the registration process[56]. - The company has launched a new portable ultrasound diagnostic system, which is expected to enhance clinical examination capabilities and expand market reach[64]. - The company has initiated the registration of several in vitro diagnostic kits, including those for serum amyloid A and C-reactive protein, indicating a strategic move towards expanding its diagnostic portfolio[70][73]. Market Expansion and Strategy - The company is exploring potential acquisitions to enhance its product portfolio and market presence[21]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[67]. - A strategic acquisition of a local competitor is anticipated to be finalized by Q4 2023, which is expected to increase market penetration by 30%[67]. - The company has expanded its distribution network, increasing the number of sales channels by 30% in the last six months[64]. - The company is focusing on innovation and internationalization, with ongoing development of new products and expansion into global markets[36]. Risk Management - Management highlighted risks including quality control and market competition, with strategies in place to mitigate these risks[3]. - The company faces quality control risks due to the technical nature of the medical device industry and has implemented measures to enhance quality management systems[116]. - The company plans to enhance foreign exchange risk management by adjusting the ratio of domestic and foreign sales based on exchange rate changes to mitigate losses[119]. - The company faces significant risks in new product development due to long R&D cycles and high investment, with potential delays in registration affecting project returns[120]. Corporate Governance and Compliance - The company has established specialized committees under the board of directors to ensure effective governance and compliance with legal requirements[137]. - The company has not issued any non-standard audit reports for the half-year financial report, which remains unaudited[146]. - The company has not faced any administrative penalties related to environmental issues during the reporting period, adhering strictly to environmental protection laws[136]. Community Engagement and Social Responsibility - The company has established a volunteer association and launched the "Light Up the Stars" public welfare project to promote community health initiatives, conducting over 70 public welfare activities in the first half of 2023, benefiting more than 5,000 people[140].

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2023-022 深圳市理邦精密仪器股份有限公司 第五届监事会 2023年第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）第五届监事会 2023 年第三次会议于 2023 年 8 月 22 日（星期二）11:30 在深圳市坪山区坑梓街道金 沙社区金辉路 15 号理邦仪器工业园会议室召开，会议通知于 2023 年 8 月 12 日 以电子邮件方式发出。会议应出席监事 3 名，实际出席监事 3 名。本次会议召开 符合《公司法》及《公司章程》的相关规定。会议由监事会主席周纯女士主持， 出席会议的监事审议并通过记名投票方式表决通过了如下决议： 1、审议通过《2023 年半年度报告及其摘要》的议案； 监事会经认真审核，认为董事会编制和审核公司 2023 年半年度报告的程序 符合法律、法规和中国证监会的有关规定，报告内容真实、准确、完整地反映了 公司 2023 年半年度经营的实际情况，不存在任何虚假记载、误导性陈述或者 ...

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2023-021 本议案具体内容详见中国证监会指定信息披露网站同日披露的相关公告。 表决结果：同意 7 票，反对 0 票，弃权 0 票，获得通过。 2、审议通过《关于公司会计政策变更》的议案； 深圳市理邦精密仪器股份有限公司 第五届董事会 2023年第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）第五届董事会 2023 年第三次会议于 2023 年 8 月 22 日（星期二）10:00 在深圳市坪山区坑梓街道金 沙社区金辉路 15 号理邦仪器工业园会议室召开，会议通知于 2023 年 8 月 12 日 以电子邮件方式发出。会议应出席董事 7 名，实际出席董事 7 名。本次会议召开 符合《公司法》及《公司章程》的相关规定。会议由董事长张浩先生主持，出席 会议的董事审议并通过记名投票方式表决通过了如下决议： 1、审议通过《2023 年半年度报告及其摘要》的议案； 1 深圳市理邦精密仪器股份有限公司 深圳市理邦精 ...

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2023-024 深圳市理邦精密仪器股份有限公司 关于公司会计政策变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）根据财政部于 2022 年颁布的《关于印发<企业会计准则解释第 16 号>的通知》的要求变更公司会计 政策。现将具体情况公告如下： 一、本次会计政策变更的概述 本次会计政策变更前，公司执行财政部发布的《企业会计准则—基本准则》 和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告以及其他 相关规定。 4、变更后采用的会计政策 本次会计政策变更后，公司将执行财政部发布的解释第 16 号。除上述会计 政策变更外，其余未变更部分，仍执行财政部颁布的《企业会计准则—基本准则》 和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告及其他相 关规定。 1、变更原因 2022 年 11 月 30 日，财政部颁布了《关于印发<企业会计准则解释第 16 号> 的通知》（财会〔2022〕31 号）(以下 ...

深圳市理邦精密仪器股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：深圳市理邦精密仪器股份有限公司 单位：人民币万元 | | | | | | | 2023 年度 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资 | | 占用方与上 | 上市公司核 | 2023 | 年期初 | 占用累计 | 2023 年度占 | 2023 年度 | 2023 年期 | 占用形 | | | 金占用 | 资金占用方名称 | 市公司的关 | 算的会计科 | | 占用资金余 | 发生金额 | 用资金的利 | 偿还累计 | 末占用资 | 成原因 | 占用性质 | | | | 联关系 | 目 | | 额 | （不含利 | 息（如有） | 发生金额 | 金余额 | | | | | | | | | | 息） | | | | | | | 控股股东、实 | | | | | | | | | | | | | 际 控 制 人 及 | | | | | | | | | | | 非经营 ...

深圳市理邦精密仪器股份有限公司 独立董事对第五届董事会2023年第三次会议相关事项的独立意见 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司 独立董事规则》、《深圳证券交易所创业板股票上市规则》、《深圳证券交易所 上市公司自律监管指引第2号——创业板上市公司规范运作》、《深圳市理邦精 密仪器股份有限公司章程》等相关规定，我们作为公司的独立董事，对公司相关 事项发表如下独立意见如下： 一、关于控股股东、实际控制人及其他关联方占用公司资金情况的独立意见 经核查，报告期内，公司不存在控股股东、实际控制人及其他关联方违规占 用公司资金的情况，也不存在以前年度发生并延续至2023年6月30日的违规关联 方资金占用情况。公司与其他关联方的资金往来符合规范性要求。 经核查，报告期内，公司不存在为控股股东及其他关联方提供担保的情形， 也不存在任何违规对外担保事项。公司严格遵守《公司法》、《深圳证券交易所 上市公司自律监管指引第2号——创业板上市公司规范运作》等相关规定，严格 控制相关风险。 三、关于公司会计政策变更的独立意见 公司依照财政部的要求，对公司会计政策相应变更，符合财政部、中国证监 会和深圳证券 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥639,691,149.30, representing a 64.21% increase compared to ¥389,562,418.35 in the same period last year[5] - Net profit attributable to shareholders was ¥140,419,036.49, a significant increase of 183.36% from ¥49,554,550.08 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥136,629,365.90, up 312.28% from ¥33,140,110.56 in the previous year[5] - Basic earnings per share rose to ¥0.2423, reflecting an increase of 184.39% compared to ¥0.0852 in the same period last year[5] - The total comprehensive income for the current period is 139,918,904.24, compared to 49,015,698.20 in the previous period, reflecting a substantial increase[41] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥2,317,584,767.18, a 3.67% increase from ¥2,235,526,845.67 at the end of the previous year[5] - Cash and cash equivalents at the end of Q1 2023 were CNY 981,762,562.67, an increase from CNY 957,004,450.27 at the beginning of the year[34] - Total assets as of March 31, 2023, were CNY 2,317,584,767.18, up from CNY 2,235,526,845.67 at the start of the year[36] - The company reported a total equity attributable to shareholders of CNY 1,992,512,134.96, an increase from CNY 1,853,056,782.31 at the beginning of the year[39] - The company’s total liabilities were CNY 1,326,346,755.57, compared to CNY 1,235,207,738.30 at the start of the year, indicating an increase in leverage[36] Cash Flow - Cash flow from operating activities increased by 46.97% to ¥36,627,250.07, compared to ¥24,921,223.37 in the same period last year[27] - Cash flow from operating activities is 36,627,250.07, compared to 24,921,223.37 in the previous period, showing an increase of about 47%[44] - The company reported a net cash outflow from investing activities of -9,051,968.36, compared to -107,849,571.75 in the previous period, showing an improvement[45] Operating Costs and Expenses - The company reported a 54.24% increase in operating costs, amounting to ¥269,126,826.78, up from ¥174,487,702.42 year-on-year[16] - The total operating costs for Q1 2023 amounted to CNY 504,390,307.61, up 39.7% from CNY 360,751,722.89 in Q1 2022[39] - Research and development expenses reached CNY 78,597,376.46, representing a 25% increase from CNY 62,947,222.23 in the previous year[39] - The company experienced a 118.31% increase in taxes and surcharges, totaling ¥6,822,216.53, compared to ¥3,124,955.41 in the previous year[16] - The company reported a decrease in other comprehensive income attributable to the parent company, with a net amount of -963,683.84 compared to 76,890.64 in the previous period[41] Sales and Revenue - The company received cash from sales of goods and services totaling 611,111,486.96, compared to 421,819,000.18 in the previous period, reflecting a growth of about 45%[44]

Financial Performance - The company's operating revenue for 2022 was CNY 1,742,412,298.64, representing a 6.48% increase compared to CNY 1,636,411,042.84 in 2021[31]. - The net profit attributable to shareholders for 2022 was CNY 232,987,942.35, a slight increase of 0.67% from CNY 231,436,439.33 in 2021[31]. - The cash flow from operating activities increased by 41.25% to CNY 335,157,849.02 in 2022, up from CNY 237,283,290.14 in 2021[31]. - The basic earnings per share for 2022 was CNY 0.4020, reflecting a 0.75% increase from CNY 0.3990 in 2021[31]. - Total assets at the end of 2022 amounted to CNY 2,235,526,845.67, a 9.15% increase from CNY 2,048,108,342.70 at the end of 2021[31]. - The company achieved operating revenue of 1,742.41 million yuan, a year-on-year increase of 6.48%[88]. - Net profit attributable to shareholders was 232.99 million yuan, up 0.67% year-on-year, while the net profit excluding non-recurring gains and losses was 200.92 million yuan, an increase of 4.94%[88]. - The gross margin improved to 45% in 2022, up from 40% in 2021, reflecting better cost management and pricing strategies[169]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year 2022, representing a 20% year-over-year growth[169]. Product Development and Innovation - In 2022, the company launched several strategic new products, including the iX series monitors and i20 blood gas analyzers, enhancing its product portfolio[7]. - The company has established a diversified business layout across six major sectors: patient monitoring, ECG diagnosis, maternal and child health, ultrasound imaging, in vitro diagnostics, and smart healthcare[51]. - The company aims to leverage its innovative capabilities and global marketing network to provide comprehensive solutions for healthcare institutions[50]. - The company has developed advanced monitoring modules for its self-developed plug-in monitoring devices, including EtCO2, anesthesia, muscle relaxant, and EEG modules, achieving core technology import substitution[56]. - The company’s continuous non-invasive blood pressure measurement technology, CNBP, is a pioneering innovation in the industry, enhancing data monitoring and user experience[56]. - The company launched several new products in 2022, including the F12 next-generation fetal monitor and the iX series new generation monitor[139]. - The company launched several new products, including the CL30 fully automated nucleic acid detection analyzer and various related testing kits, enhancing its product relevance and competitive edge in the molecular diagnostics field[141]. - The introduction of a fetal and maternal monitor demonstrates the company's expansion into maternal health monitoring technologies[154]. - The company is actively pursuing innovation in medical technology, as evidenced by its ongoing registration efforts for new devices and updates to existing products[156]. Market Expansion and Global Presence - The company expanded its international presence by establishing subsidiaries in Kenya and Thailand, further developing its global marketing channels[7]. - The company aims to strengthen localization in international markets, ensuring high-quality equipment and localized after-sales service[10]. - The company has established a comprehensive after-sales service system covering over 170 countries and regions, providing 24/7 support[97]. - The company has integrated its domestic and international marketing teams, significantly improving global marketing efficiency[96]. - The company plans to continue strengthening its global marketing network to support future product expansion and market share growth[96]. - The company is expanding its market presence in Southeast Asia, targeting a 25% increase in market share by the end of 2023[179]. Research and Development - R&D investment for the reporting period was CNY 297.54 million, an increase of 17.95% year-on-year, accounting for 17.08% of the total revenue[93]. - The number of R&D personnel increased by 14.66% to 743 in 2022, with a notable rise in the proportion of staff holding bachelor's and master's degrees[143]. - The company is investing 200 million RMB in R&D for new monitoring technologies over the next three years[162]. - The company is investing in R&D for advanced diagnostic ultrasound systems, with a budget allocation of 100 million RMB for the next fiscal year[179]. Regulatory Approvals and Compliance - The company is currently in the registration process for multiple medical devices, including an ECG analysis software and patient monitors, with the ECG software classified as Class III and under technical review[146]. - The company has obtained NMPA registration for multiple ECG devices, including single-channel and multi-channel ECG machines, with registration dates ranging from April 2020 to June 2022, and expiration dates extending to 2025[156]. - The company is actively pursuing regulatory approvals for new products, which reflects its commitment to enhancing its medical device portfolio and market presence[149]. - The registration process for these devices is crucial for the company's growth strategy, as it aims to meet the increasing demand for advanced medical monitoring solutions[149]. Customer Engagement and Service - The company has established a strong online academic platform, hosting over 600 training sessions and attracting more than 200,000 healthcare professionals, enhancing its brand influence[111]. - The company provided health management and telemedicine services to over 300 medical institutions, completing more than 2 million ECG diagnostic services and over 1 million maternal and child health management services[120]. - The company has set up over 30 training bases for dynamic electrocardiogram training across the country, enhancing customer service capabilities[98]. Strategic Acquisitions - A strategic acquisition of a local competitor is anticipated to enhance the company's product portfolio and increase market penetration, expected to close by Q3 2023[170]. - The company completed a strategic acquisition of a competitor, which is anticipated to increase market share by 5%[200]. Future Outlook - The company provided a positive outlook for 2023, projecting a revenue growth of 15% to 1.725 billion RMB, driven by new product launches and market expansion strategies[169]. - The company has set a future outlook with a revenue guidance of 1.5 billion RMB for the next fiscal year, indicating a projected growth of 25%[162].

深圳市理邦精密仪器股份有限公司 投资者依据提示，授权登入"理邦仪器投资者关系"小程序，即可参与交流。 出席本次年度业绩说明会的人员有：公司董事长、总裁张浩先生，副总裁、 董事会秘书、财务负责人祖幼冬先生，财务执行总监林静媛女士，独立董事苏洋 先生。 1 证券代码：300206 证券简称：理邦仪器 公告编号：2023-005 深圳市理邦精密仪器股份有限公司 关于举行2022年度网上业绩说明会并征集相关问题的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）将于2023年4月7 日（星期五）下午15:00至17:00，在"理邦仪器投资者关系"小程序举行2022 年度网上业绩说明会，本次网上业绩说明会将采用网络远程的方式举行，投资 者可登陆"理邦仪器投资者关系"小程序参与互动交流。 参与方式一：在微信中搜索"理邦仪器投资者关系"； 参与方式二：微信扫一扫以下二维码： 深圳市理邦精密仪器股份有限公司 为进一步做好中小投资者保护工作，增进投资者对公司的了解和认同，以提 升公司治理水平和企业整体价值，现就公司2022年 ...